Novartis AG $NVS Shares Sold by Delphi Management Inc. MA

Delphi Management Inc. MA lessened its position in Novartis AG (NYSE:NVS) by 31.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,988 shares of the company’s stock after selling 3,735 shares during the quarter. Novartis makes up 1.5% of Delphi Management Inc. MA’s investment portfolio, making the stock its 22nd largest holding. Delphi Management Inc. MA’s holdings in Novartis were worth $1,220,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NVS. Fisher Asset Management LLC lifted its holdings in Novartis by 1.7% during the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock worth $928,376,000 after buying an additional 117,952 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Novartis by 18.1% in the third quarter. JPMorgan Chase & Co. now owns 537,543 shares of the company’s stock worth $68,935,000 after acquiring an additional 82,226 shares in the last quarter. BXM Wealth LLC grew its stake in shares of Novartis by 726.9% in the fourth quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock worth $5,903,000 after acquiring an additional 37,639 shares in the last quarter. Spire Wealth Management increased its position in shares of Novartis by 2,561.0% during the fourth quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock worth $5,375,000 after acquiring an additional 37,518 shares during the period. Finally, AlphaCore Capital LLC increased its position in shares of Novartis by 197.1% during the third quarter. AlphaCore Capital LLC now owns 22,964 shares of the company’s stock worth $2,945,000 after acquiring an additional 15,235 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVS. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a report on Thursday, March 19th. Argus upgraded Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Wednesday, March 11th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Finally, Morgan Stanley lifted their price objective on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $141.20.

Novartis Trading Down 0.1%

Shares of NYSE:NVS opened at $153.28 on Thursday. Novartis AG has a 52 week low of $112.34 and a 52 week high of $170.46. The company’s 50 day moving average is $148.95 and its two-hundred day moving average is $149.30. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The company has a market cap of $292.49 billion, a PE ratio of 21.96, a P/E/G ratio of 2.70 and a beta of 0.46.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. Novartis’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.28 earnings per share. Equities analysts predict that Novartis AG will post 8.82 earnings per share for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.